SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted
In the news release, New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026, issued 01-Oct-2026 by Nektar
Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanismIn alopecia areata
Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical responseSAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- Nektar Therapeutics
New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areataCompany to host conference call with investors and analysts on
SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted
SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2wFirst large, placebo-controlled trial to support T-reg modulation as
SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ:NKTR) breached their fiduciary duties to
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S.-based
SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified
Two global registrational Phase 3 trials initiated in ZENITH AD programPhase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with monthly and
SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified
